Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm

New York, New York--(Newsfile Corp. - September 4, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Insiders at Rocket Pharmaceuticals caused the company to provide investors with material information concerning Rocket's Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease. The statements included, among other things, confidence in the drug's safety and efficacy, as well as the clinical trial's detailed protocol and Rocket's purported ability to meet the trial's endpoints as per the Company's ascribed timeline. While, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RPA501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.

If you currently own RCKT and purchased prior to February 27, 2025 please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265153